Kamada Doubles Israeli Biosimilar Portfolio, Sets $20M-$25M Revenue Target by 2030
KMDA sits 24% above its 52-week low of $6.5.
Summary
Kamada launched two additional biosimilar products in Israel and provided multi-year revenue guidance for its biosimilars portfolio, targeting $20M-$25M in annual revenue by 2030.
Key Events · Product Development and Regulatory · KMDA
-
Two New Biosimilars Launched in Israel
The company launched Ustekinumab-Kamada (biosimilar to Stelara) and Enoxaparin-Kamada (biosimilar to Clexane), doubling its marketed biosimilar portfolio to four products.
-
Multi-Year Revenue Guidance Provided
Biosimilars portfolio expected to generate approximately $4M in 2026, $10M in 2028, and $20M-$25M annually by 2030.
-
Portfolio Expansion Roadmap
Company expects at least two additional biosimilar launches in 2027 and at least 12 marketed products from 6 licensing partners by 2030, commercialized in Israel and the MENA region.
-
Strategic Growth Pillar
CEO Amir London stated the biosimilars portfolio is a key strategic growth pillar, with the company continuing to evaluate additional in-licensing opportunities.
Analysis · KMDA · Life Sciences
The biosimilars segment is becoming a meaningful growth pillar for Kamada, which now has four marketed products in Israel and expects two more in 2027. Management has provided concrete multi-year revenue guidance for this business: approximately $4 million in 2026, rising to $10 million in 2028 and $20 million to $25 million by 2030. For a company with a market cap around $460 million, this gives investors a quantifiable path for biosimilars to become a material contributor to overall revenue.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KMDA was trading at $8.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $461.6M. The 52-week trading range was $6.50 to $9.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.